SARS-CoV-2 spike E484K mutation reduces antibody neutralisation

Affiliations

• ¹ Department of Microbiology, Icahn School of Medicine at Mount Sinai New York, NY 10029, USA; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai New York, NY 10029, USA.
• ² Texas Biomedical Research Institute, San Antonio, TX, USA.
• ³ Department of Microbiology, Icahn School of Medicine at Mount Sinai New York, NY 10029, USA; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai New York, NY 10029, USA; Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai New York, NY 10029, USA.
• ⁴ Department of Microbiology, Icahn School of Medicine at Mount Sinai New York, NY 10029, USA.
• ⁵ Department of Microbiology, Icahn School of Medicine at Mount Sinai New York, NY 10029, USA; Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai New York, NY 10029, USA; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai New York, NY 10029, USA.
• ⁶ Department of Microbiology, Icahn School of Medicine at Mount Sinai New York, NY 10029, USA; Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai New York, NY 10029, USA; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai New York, NY 10029, USA; The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai New York, NY 10029, USA. Electronic address: adolfo.garcia-sastre@mssm.edu.
• ⁷ Department of Microbiology, Icahn School of Medicine at Mount Sinai New York, NY 10029, USA; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai New York, NY 10029, USA. Electronic address: michael.schotsaert@mssm.edu.